FY2024 EPS Estimates for electroCore Cut by Analyst

electroCore, Inc. (NASDAQ:ECOR) – Investment analysts at Brookline Capital Management decreased their FY2024 earnings per share estimates for shares of electroCore in a research note issued to investors on Thursday, November 14th. Brookline Capital Management analyst T. Bussian now expects that the company will earn ($1.40) per share for the year, down from their prior estimate of ($1.03). The consensus estimate for electroCore’s current full-year earnings is ($1.44) per share. Brookline Capital Management also issued estimates for electroCore’s Q4 2024 earnings at ($0.33) EPS.

electroCore Stock Up 4.6 %

Shares of ECOR stock opened at $10.09 on Monday. The firm has a market capitalization of $66.09 million, a P/E ratio of -5.51 and a beta of 0.56. electroCore has a twelve month low of $5.02 and a twelve month high of $14.20. The stock’s fifty day simple moving average is $9.04 and its 200 day simple moving average is $7.29.

Institutional Trading of electroCore

Several hedge funds and other institutional investors have recently made changes to their positions in ECOR. International Assets Investment Management LLC raised its holdings in electroCore by 689.1% in the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock valued at $3,864,000 after buying an additional 467,326 shares during the last quarter. Renaissance Technologies LLC increased its position in electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after acquiring an additional 2,270 shares during the period. Geode Capital Management LLC raised its stake in shares of electroCore by 10.3% during the third quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after acquiring an additional 5,951 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new position in shares of electroCore during the third quarter worth $255,000. 26.74% of the stock is currently owned by institutional investors.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.